A5074693766- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Genetic Syndromes and Imprinting
- Circular RNAs in diseases
- Respiratory viral infections research
- Kruppel-like factors research
- Nutrition and Health in Aging
- Cancer survivorship and care
- Single-cell and spatial transcriptomics
- Artificial Intelligence in Healthcare and Education
- Brain Metastases and Treatment
- Organ Donation and Transplantation
- Renal and Vascular Pathologies
- COVID-19 diagnosis using AI
- RNA modifications and cancer
- Cancer-related gene regulation
- vaccines and immunoinformatics approaches
- Radiomics and Machine Learning in Medical Imaging
- Frailty in Older Adults
- Pediatric Urology and Nephrology Studies
- Viral gastroenteritis research and epidemiology
Sun Yat-sen University Cancer Center
2022-2025
Sun Yat-sen University
2022-2025
Shaanxi Provincial People's Hospital
2024
State Key Laboratory of Oncology in South China
2022-2024
Shanxi Medical University
2024
Second Affiliated Hospital of Zhejiang University
2024
The continuous emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants highlights the need to update coronavirus 2019 disease (COVID-19) vaccine components. Epitope-based designs targeting conserved and immunorecessive regions SARS-CoV-2 are critically needed. Here, we report an engineered epitope-focused immunogen design based on a novel horseshoe-shaped natural protein scaffold, named ribonuclease inhibitor 1 (RNH1), that can multiply display neutralizing...
Abstract Objective Receptor-interacting protein 2 (RIP2) is an essential mediator of inflammation and innate immunity downstream pattern recognition receptors (PRRs). Platelets express RIP2, while its role in platelet activation, thrombosis, myocardial infarction (MI) unknown. Approach Results Here we show that RIP2 deficiency enhances dense granule secretion response to GPIb GPVI activation; aggregation whole blood adhesion under arterial shear are also increased. Consistently, inhibitor...
Immune surveillance and chemotherapy sensitivity play critical functions in the tumorigenesis of breast cancer (BC). Emerging findings have indicated that circular RNA (circRNA) N
Non-cancer events are important causes of competing mortality among cancer patients. However, the risk non-cancer death and classification in middle-aged patients is not clear. To comprehensively analyze deaths 24 different cancers Standardized rate (SMR), absolute excess (AER), proportion deaths, age-adjusted (AAMR), model were used to assess A was developed for types based on (hazard ratio). total 1,082,030 identified. The elevated compared general population (SMR = 3.37, 95 % CI...
Fumarate hydratase-deficient renal cell carcinoma (FHRCC) is highly malignant, but the urgent need for effective treatment remains unmet. We aimed to analyze genomic characteristics and microenvironment of FHRCC cause heterogeneous response immune checkpoint inhibitor (ICI)-based at single-cell level.Whole-exome sequencing IHC staining analyses were performed in 30 advanced patients. Single-cell RNA following ICI-based was conducted 4 The clinical characteristics, therapeutic effect,...
e16519 Background: The combination of immune checkpoint inhibitor (ICI) and tyrosine kinase (TKI) has emerged as the standard first-line therapy for metastatic renal cell carcinoma (mRCC), however, limited clinical trials have investigated role ICI plus TKI in treatment non-clear (mnccRCC) its heterogeneity low incidence. Our study presents multiple center real-world data with optimal sample size so far to assess efficacy safety profile patients mnccRCC. Methods: We performed a retrospective...
Abstract Cancer stem cells (CSCs) play crucial roles in tumor metastasis, therapy resistance, and immune evasion. Identifying understanding the factors that regulate stemness of presents promising opportunities for developing effective therapeutic strategies. In this study on oral squamous cell carcinoma (OSCC), we confirmed key role KLF7 maintaining OSCC. Using chromatin immunoprecipitation sequencing dual-luciferase assays, identified ITGA2, a membrane receptor, as downstream gene...
<div>AbstractPurpose:<p>Fumarate hydratase–deficient renal cell carcinoma (FHRCC) is highly malignant, but the urgent need for effective treatment remains unmet. We aimed to analyze genomic characteristics and microenvironment of FHRCC cause heterogeneous response immune checkpoint inhibitor (ICI)-based at single-cell level.</p>Experimental Design:<p>Whole-exome sequencing IHC staining analyses were performed in 30 advanced patients. Single-cell RNA following...
Supplementary Data from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Data from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Data from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Figure from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Figure from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Data from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Data from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Figure from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Figure from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Data from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Data from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Figure from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Figure from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Data from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Figure from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma